3 Insights on

• Improved Stool Consistency
• Reduced Stool Consistency
• Reduced Radiation-Induced Diarrhea Incidence

7 Insights on

• Reduced T Cell Responsiveness
• Reduced Proliferation of CD4(+) T Cells
• Increased Apoptosis in T Cells
• Increased IFN-gamma Secretion from Naïve T Cells
• Reduced IL-4 Secretion from Naïve T Cells
• Modulated Dendritic Cell Function
• Increased Apoptosis of OVA-specific TCR Tg T Cells

4 Insights on

• Increased Triglyceride Level
• Reduced Bone-Specific Alkaline Phosphatase Level
• Increased Endometrial Thickness
• Improved Breast Tissue Structure

6 Insights on

• Altered T Cell Subsets
• Increased CD4+ and CD8+ T Cell Proportion
• Reduced CTLA-4 Induction on CD4 T Cells
• Increased Ileal Enterobacteriaceae Counts
• Increased Interleukin-8 Expression in the Ileum
• Reduced CTLA-4 Expression on CD4 T Cells

4 Insights on

• Reduced Salmonella Enterica Invasion
• Reduced Pathogen Infection
• Enhanced Bile Salt Resistance
• Reduced Salmonella sonnei Infection

4 Insights on

• Improved Intestinal Barrier Integrity
• Maintained Intestinal Barrier Function
• Improved Epithelial Protection
• Protection Against Cellular Damage Induced by Pathogens

2 Insights on

• Increased CD4 Counts
• Resolved Moderate Diarrhea

2 Insights on

• Increased Bifidobacterial Population
• Improved Prebiotic Index

3 Insights on

• Reduced Inflammatory Response
• Reduced Baseline IL-8 Secretion
• Improved Barrier Integrity

5 Insights on

• Improved Antibacterial Activity
• Improved Innate Immune Response
• Enhanced Respiratory Burst Activity
• Increased Granulocyte Count
• Improved Serum Bactericidal Activity

1 Insight on

• Reduced Salivary Levels of Mutans Streptococci

7 Insights on

• Reduced Body Weight
• Improved Crypt Hyperplasia
• Reduced Histological Damage
• Reduced Myeloperoxidase Activity
• Decreased Mannitol Flux
• Reduced Mucosal Adherent Citrobacter rodentium
• Maintained Colonic Epithelial Barrier Integrity

3 Insights on

• Reduced Ulcerative Colitis Symptoms
• Increased IL-10 Production
• Reduced Risk of Salmonella Infection

1 Insight on

• Increased Clostridium perfringens Density

4 Insights on

• Reduced Immunoglobulin E Production
• Reduced Ovalbumin-Specific IgE Production
• Improved Th1/Th2 Balance
• Reduced Histamine Release

2 Insights on

• Increased Interleukin-12 Production
• Improved Immunostimulatory Activity

6 Insights on

• Increased PMN Cell Phagocytic Capacity
• Reduced TNF-α Levels
• Reduced Incidence of Common Infectious Diseases
• Increased Hemoglobin Levels
• Improved Serum Albumin Levels
• Reduced Incidence of Infections

2 Insights on

• Improved Vaginal Maturation Index
• Reduced Vaginal Dryness

3 Insights on

• Reduced Intestinal Permeability
• Increased Head Circumference
• Increased Bifidobacterial Counts

20 Insights on

• No Adverse Effects on Body Weight or Food Intake
• Absence of Treatment-Associated Bacterial Translocation
• Significant Bacterial Translocation with Intraperitoneal Administration
• Increased Plasma Serum Alpha-Amyloid Protein
• Nonpathogenic Even at High Doses
• Ensured Safety for Human Consumption
• Reduced Bacterial Translocation
• Absence of Bacteremia
• No Hepatic or Splenic Translocation with Oral Administration
• No Illness or Death Despite Bacterial Translocation
• Nonpathogenic Condition
• No Bacteremia or Translocation of Bacteria to Vital Organs
• Absence of Bacterial Translocation to Liver or Spleen
• No Illness or Death from Bacterial Translocation (Intraperitoneal Administration)
• No Bacteremia
• No Adverse Weight or Intake Effects in Mice
• Nonpathogenic for Mice
• Maintained Body Weight
• No Adverse Effects from Intraperitoneal Administration
• Increased Serum Amyloid Protein

5 Insights on

• Improved Epithelial Permeability
• Improved Gut Permeability
• Reduced Visceral Pain
• Reduced Stress-Mediated Visceral Hyperalgesia
• Prevented Visceral Hyperalgesia

1 Insight on

• Enhanced Antioxidative Capacity

4 Insights on

• Reduced Risk of Listeria Monocytogenes Infection
• Enhanced Protection Against Infection
• Reduced Susceptibility to Infection
• No Protection Against Listeria Monocytogenes

2 Insights on

• Reduced Duration of Diarrhea
• Well Tolerated Treatment

2 Insights on

• Reduced Pathogen Growth
• Improved Intestinal Cell Adhesion

1 Insight on

• Reduced Potential Pathogenic Bacteria

3 Insights on

• Reduced Fecal Microbiota Diversity
• Improved Fecal Microbiota Diversity
• Increased Tetracycline Resistance

3 Insights on

• Increased SalA-like Inhibitory Activity
• Reduced Risk of S. pyogenes Infection
• Enhanced Protection Against Streptococcus Pyogenes Infection

12 Insights on

• Enhanced Natural Killer Cell Tumoricidal Activity
• Improved Natural Killer Cell Activity
• Reduced Incidence of Influenza
• Increased IL-12 Levels
• Increased NK Cell Activity
• Improved Immune Response to Influenza Vaccination
• Increased Antigen-Specific Immunoglobulin A
• Increased Natural Killer Cell Proportion
• Reduced Incidence of Influenza-like Illness
• Increased Immunoglobulin M Levels
• Improved Specific Antibody Response
• Increased T-helper Type 1 Cytokine Concentrations

9 Insights on

• Reduced Total Cholesterol Levels
• Increased Lactic Acid Bacteria Levels
• Reduced Triglyceride Levels
• Change in Body Weight
• Reduced Serum Cholesterol Levels
• Reduced Serum Triglycerides
• Reduced Triglycerides
• Reduced Serum Cholesterol
• Increased Fecal Lactic Acid Bacteria Counts